When Raphael was diagnosed with a mutation in the STXBP1 gene, we knew that finding a cure would not be simple. A logical plan was needed to ensure that all efforts would help us reach our goal of helping Raphael and other kids in similar conditions as quickly as possible.
In this blog, we will look closely at what makes a strategic plan successful and why it is so important. I will explain how it works as a guide for our mission and share the specific phases and actions we have taken to move forward in our search for a cure. Let’s get started.
Why Do We Need a Plan?
The journey to develop therapeutics for STXBP1 disorders is complex and multifaceted, requiring meticulous coordination and a clear roadmap. Without a strategic plan, efforts can become disjointed, resources may be wasted, and the ultimate goal of finding a cure could be delayed. A well-crafted strategic plan ensures that every step taken is purposeful and directed toward our mission: to transform the lives of Raphael and many other children who suffer from rare genetic diseases.
In my last blog post, I discussed the five key steps that allowed us to kick-start our research and were essential for building our strategic plan.
To recap, we talked about:
- Understanding Biology – We had to learn the basics of biology to communicate effectively with researchers and scientists.
- Getting Familiar with STXBP1 – Learning everything we can about STXBP1 research and knowledge.
- Expanding Our Network – Mapping all the relevant researchers and contacts who could help to advance our mission.
- Establishing Disease Models – Preparing the foundations of our groundbreaking research.
- Building a Strategic Plan – Developing a plan that will guide us to finding a cure.
Let’s dive into the foundations of what makes a strategic plan successful and so essential.
How a Strategic Plan Helps
A strategic plan serves as a blueprint for our efforts at Rafa’s Moonshot. It outlines our goals, identifies the resources needed, and establishes a timeline for achieving our objectives. This structured approach helps in several key ways:
- Focus and Direction: It aligns all stakeholders—researchers, clinicians, pharma, biotech, and parent-led organizations—towards common goals, ensuring everyone works cohesively.
- Resource Allocation: It enables the efficient use of funds and resources, directing them to the areas of highest impact.
- Progress Tracking: It provides measurable milestones and benchmarks, allowing us to monitor progress and adjust strategies as needed.
- Stakeholder Engagement: It keeps all stakeholders informed and engaged, showcasing our commitment and the impact of our approach.
Rafa’s Moonshot: Our Strategic Plan for a Cure
When the doctor delivered the devastating news, “There is no cure,” Ella and I were heartbroken. However, we chose not to accept defeat. In the following weeks, we started to develop a strategic plan to find an effective treatment and, ultimately, a cure. Our plan is divided into three distinct phases that are running in parallel.
Short, Mid and Long-term Therapeutics
When we started our journey, Ella and I mapped the different existing therapeutic strategies, identified what currently exists in the market, and what will be relevant in the future. We knew that we needed to divide our plan into several time frames—the here and now (short term), developing therapeutics with existing and validated technologies (midterm), and constantly scouting for new technologies that enter the market within five years and beyond.
In our specific case, we did the following segmentation:
Drug Repurposing Initiatives (Short Term): Investment in projects focused on identifying existing FDA-approved drugs with the potential to stabilize the STXBP1 mutation or upregulate protein levels.
Developing Personalized Genetic Therapies (Mid Term): Transition promising therapies from laboratory settings into clinical trials, focusing on existing technologies like Antisense Oligonucleotides (ASO) and gene therapy approaches.
Pioneering Future Cures (Long Term): Actively seeking and evaluating cutting-edge technologies in gene therapies, including CRISPR/Cas9 applications, and establishing partnerships with technology companies to integrate breakthrough innovations into STXBP1 research.
Clinical Trial Readiness
Mechanism Exploration: Supporting studies aimed at understanding the precise mechanisms underlying STXBP1-related disorders, encouraging innovative approaches at the molecular and cellular levels.
Disease Model Development: Funding the creation and refinement of accurate disease models, such as iPSCs, organoids, and organisms like C. elegans and rodents, to establish platforms for preclinical trials.
Biomarker Identification: Backing projects dedicated to discovering reliable biomarkers for early detection, prognosis, and treatment response assessment in STXBP1 disorders, and collaborating with diagnostic and biotech companies to translate these discoveries into practical applications.
Implementation Plan
Grant Programs: Establishing competitive grant programs to encourage high-impact research proposals from top researchers worldwide.
Building Collaborations: Forging partnerships with leading academic and research institutions globally to accelerate STXBP1 research and expand our network. Additionally, we’re engaging with pharmaceutical companies, biotech firms, and influencers to broaden our reach and impact.
Pharmaceutical Engagement: Initiating discussions and partnerships with pharmaceutical companies to leverage their expertise and increase their commitment to STXBP1 disorders.
Transparency and Updates: Providing regular updates about our research to the global STXBP1 community, supporters, researchers, and stakeholders to enhance collaboration and accelerate progress.
Final Thoughts
Creating a strategic plan for Rafa’s Moonshot was a crucial step in a challenging yet rewarding journey. Each phase, from understanding the biology and specific challenges of STXBP1 to expanding our network and developing disease models, has been instrumental in guiding our mission.
The most significant achievement for us has been the development of two therapies in less than a year. Raphael has been taking one of the drugs we discovered just six months after diagnosis on a daily basis, and we are witnessing remarkable improvement day after day.
Our journey is fueled by the unwavering belief that no challenge is insurmountable with determination and a clear plan. As we continue to support new research, develop precise disease models, and identify reliable biomarkers, we are laying a strong foundation for clinical trial readiness and future breakthroughs.
We invite you to join us in this mission. Every step forward brings us closer to changing the lives of children like Raphael and many others around the world.
